Advertisement

Clinical & Experimental Metastasis

, Volume 36, Issue 3, pp 199–209 | Cite as

Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer

  • Congcong Wu
  • Wenjun Chen
  • Jian Wu
  • Xi Zhang
  • Xuanzhang Huang
  • Ruifang Lin
  • Baoling Zhu
  • Hua JiangEmail author
Review
  • 112 Downloads

Abstract

Adjuvant therapy with bisphosphonates in prostate cancer is effective in improving bone mineral density and thus reducing fractures and skeletal-related events. We analyzed the effect of bisphosphonates on overall survival (OS) in subgroups of patients with prostate cancer. A systematic literature search was conducted of the PubMed database and the bibliographies of related studies. The long-term OS rates were extracted from every eligible trial. The hazard ratio (HR) was pooled with the fixed effects model, and preplanned subgroup analyses were performed. The search yielded 112 articles, of which 10 articles with 13 patient subgroups met the eligibility criteria. The meta-analysis of all 13 subgroups showed that adjuvant bisphosphonate therapy did not significantly improve OS versus the control group (HR = 0.961, 95% CI 0.899–1.026, p = 0.233) with low heterogeneity (I2 = 13.47%, degrees of freedom = 12, p = 0.336). There was no significant improvement in OS with the addition of bisphosphonates in the major subgroup analyses (metastatic (M1) versus non-metastatic, clodronate versus zoledronic acid, castration-sensitive prostate cancer (CSPC) versus castration-refractory prostate cancer). When the subgroups were further divided, adjuvant bisphosphonate therapy significantly improved OS in patients with CSPC + M1 (HR = 0.874, 95% CI 0.778–0.982, p = 0.023; I2 = 0.0%, degrees of freedom = 3, p = 0.579). Our study demonstrated that bisphosphonates do not significantly improve long-term OS in patients with prostate cancer. However, adjuvant bisphosphonate therapy significantly improves OS in the subgroup of patients with CSPC + M1.

Keywords

Prostatic neoplasms Overall survival Bisphosphonates Meta-analysis 

Notes

Acknowledgements

We thank Kelly Zammit, BVSc, from Liwen Bianji, Edanz Editing China (http://www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Funding

No specific funding was received for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, LyonGoogle Scholar
  2. 2.
    Canadian Cancer Society (2017) Prostate cancer statistics. http://www.cancer.ca/en/cancer-information/cancer-type/prostate/statistics/?region=sk
  3. 3.
    Sharifi N, Gulley JL, Dahut WL (2010) An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 17:R305–R315CrossRefGoogle Scholar
  4. 4.
    Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388–2399CrossRefGoogle Scholar
  5. 5.
    Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC (2006) The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 98:973–978CrossRefGoogle Scholar
  6. 6.
    Denis L, Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72:3888–3895CrossRefGoogle Scholar
  7. 7.
    Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179CrossRefGoogle Scholar
  8. 8.
    de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005CrossRefGoogle Scholar
  9. 9.
    Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRefGoogle Scholar
  10. 10.
    Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRefGoogle Scholar
  11. 11.
    Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520CrossRefGoogle Scholar
  12. 12.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164CrossRefGoogle Scholar
  13. 13.
    Berruti A, Dogliotti L, Terrone C et al (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361–2367; discussion 2367CrossRefGoogle Scholar
  14. 14.
    Krupski TL, Smith MR, Lee WC et al (2004) Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101:541–549CrossRefGoogle Scholar
  15. 15.
    Wu C, Chen W, Huang X, Lin R, Wu J, Zhang X (2018) Effect of diphosphonates on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Clin Genitourin Cancer 16:e1243–e1250CrossRefGoogle Scholar
  16. 16.
    Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822CrossRefGoogle Scholar
  17. 17.
    Smith MR, Morton RA, Barnette KG et al (2013) Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 189:S45–S50Google Scholar
  18. 18.
    Bolger JJ, Dearnaley DP, Kirk D et al (1993) Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. Group Semin Oncol 20:32–33;UK Metastron InvestigatorsGoogle Scholar
  19. 19.
    Autio KA, Pandit-Taskar N, Carrasquillo JA et al (2013) Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer 119:3186–3194CrossRefGoogle Scholar
  20. 20.
    Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223CrossRefGoogle Scholar
  21. 21.
    Montague R, Hart CA, George NJ, Ramani VA, Brown MD, Clarke NW (2004) Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol 46:389–401CrossRefGoogle Scholar
  22. 22.
    Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10:872–876CrossRefGoogle Scholar
  23. 23.
    James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163–1177CrossRefGoogle Scholar
  24. 24.
    Denham JW, Joseph D, Lamb DS et al (2014) Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 15:1076–1089CrossRefGoogle Scholar
  25. 25.
    Kamba T, Kamoto T, Maruo S et al (2017) A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. Int J Clin Oncol 22:166–173CrossRefGoogle Scholar
  26. 26.
    James ND, Pirrie SJ, Pope AM et al (2016) Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both: the TRAPEZE Randomized Clinical Trial. JAMA Oncol 2:493–499CrossRefGoogle Scholar
  27. 27.
    Pan Y, Jin H, Chen W et al (2014) Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. Int Urol Nephrol 46:2319–2326CrossRefGoogle Scholar
  28. 28.
    Wirth M, Tammela T, Cicalese V et al (2015) Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol 67:482–491CrossRefGoogle Scholar
  29. 29.
    Smith MR, Halabi S, Ryan CJ et al (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143–1150CrossRefGoogle Scholar
  30. 30.
    Meulenbeld HJ, van Werkhoven ED, Coenen JL et al (2012) Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 48:2993–3000CrossRefGoogle Scholar
  31. 31.
    Ernst DS, Tannock IF, Winquist EW et al (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21:3335–3342CrossRefGoogle Scholar
  32. 32.
    Satoh T, Kimura M, Matsumoto K et al (2009) Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 115:3468–3474CrossRefGoogle Scholar
  33. 33.
    Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978CrossRefGoogle Scholar
  34. 34.
    Body JJ, Bartl R, Burckhardt P et al (1998) Current use of bisphosphonates in oncology. J Clin Oncol 16:3890–3899CrossRefGoogle Scholar
  35. 35.
    Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453–475CrossRefGoogle Scholar
  36. 36.
    Coleman RE (2009) Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 45:1909–1915CrossRefGoogle Scholar
  37. 37.
    Brown JE, Neville-Webbe H, Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11:207–224CrossRefGoogle Scholar
  38. 38.
    Poon Y, Pechlivanoglou P, Alibhai SMH et al (2018) Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 121:17–28CrossRefGoogle Scholar
  39. 39.
    DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876CrossRefGoogle Scholar
  40. 40.
    Ullen A, Lennartsson L, Harmenberg U et al (2005) Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 44:644–650CrossRefGoogle Scholar
  41. 41.
    Vale CL, Burdett S, Rydzewska LHM et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243–256CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Chemotherapy and RadiotherapyThe Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical UniversityWenzhouChina
  2. 2.Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, The Key Laboratory of Nephropathy and the Kidney Disease Immunology Laboratory, The Third Grade LaboratoryHangzhouChina

Personalised recommendations